Integrated Filing — IndAS



General information about company

Scrip Code 542650
NSE Symbol METROPOLIS
MSEI Symbol NOTLISTED
ISIN INE112L01020
Name of company Metropolis Healthcare Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 13-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 07-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pathology Services
Start date and time of board meeting 13-05-2026   14:16:00
End date and time of board meeting 13-05-2026   17:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 07-08-2025
Indicate Company website link for updated RPT policy of the Company https://www.metropolisindia.com/newdata/investors/data/disclosures_under_regulation_46_of_lodr/policyonrelatedpartytransaction.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No such events during the quarter



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 35,203.12 1,36,547.17
Other income 881.67 1,633.12
Total income 36,084.79 1,38,180.29
2 Expenses
(a) Cost of materials consumed 6,081.79 25,271.78
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 7,492.76 29,743.84
(e) Finance costs 656.12 1,918.69
(f) Depreciation, depletion and amortisation expense 3,279.69 11,616.74
(f) Other Expenses
1 Laboratory testing charges 568.97 1,801.80
2 Other expenses 12,044.25 45,907.51
Total other expenses 12,613.22 47,709.31
Total expenses 30,123.58 1,16,260.36
3 Total profit before exceptional items and tax 5,961.21 21,919.93
4 Exceptional items 0.00 (795.67)
5 Total profit before tax 5,961.21 21,124.26
6 Tax expense
7 Current tax 1,889.62 5,755.61
8 Deferred tax (254.48) (345.45)
9 Total tax expenses 1,635.14 5,410.16
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 4,326.07 15,714.10
12 Profit (loss) from discontinued operations before tax (3.28) 45.75
13 Tax expense of discontinued operations (0.83) 11.52
14 Net profit (loss) from discontinued operation after tax (2.45) 34.23
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 4,323.62 15,748.33
17 Other comprehensive income net of taxes 44.06 (17.53)
18 Total Comprehensive Income for the period 4,367.68 15,730.80
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 4,146.57 4,146.57
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 1,34,763.96
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 2.09 7.6
Diluted earnings (loss) per share from continuing operations 2.09 7.6
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0.02
Diluted earnings (loss) per share from discontinued operations 0 0.02
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.09 7.62
Diluted earnings (loss) per share from continuing and discontinued operations 2.09 7.62
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Refer the financial results pdf uploaded on stock exchange for the full notes



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 17,480.30
Capital work-in-progress
Investment property
Goodwill 41,542.55
Other intangible assets 38,062.91
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 34,895.74
Trade receivables, non-current
Loans, non-current 136.26
Other non-current financial assets
1 Other financial assets 1,794.77
Total of other non-current financial assets 1,794.77
Total non-current financial assets 36,826.77
Deferred tax assets (net) 1,551.56
Other non-current assets
1 Other non-current assets 16,962.74
Total of other non-current assets 16,962.74
Total non-current assets 1,52,426.83
2 Current assets
Inventories 3,221.02
Current financial asset
Current investments 13,477.60
Trade receivables, current 11,887.05
Cash and cash equivalents 2,006.35
Bank balance other than cash and cash equivalents 48.50
Loans, current 79.80
Other current financial assets
Total of other current financial assets 1,136.82
Total current financial assets 28,636.12
Current tax assets (net)
Other current assets
1 Other current assets 2,762.16
Total of other current assets 2,762.16
Total current assets 34,619.30
3 Non-current assets classified as held for sale 1.89
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 1,87,048.02
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 4,146.57
Other equity 1,34,763.96
Total equity attributable to owners of parent 1,38,910.53
Non controlling interest
Total equity 1,38,910.53
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Other non-current financial liabilities 11,964.00
Total of other non-current financial liabilities 11,964.00
Total non-current financial liabilities 11,964.00
Provisions, non-current 2,918.89
Deferred tax liabilities (net) 6,713.18
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 21,596.07
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 343.59
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 11,183.11
Total Trade payable 11,526.70
Other current financial liabilities
1 Lease Liability 6,367.14
2 Other current financial liabilities 1,549.65
Total of other current financial liabilities 7,916.79
Total current financial liabilities 19,443.49
Other current liabilities 1,710.46
1 Other current liabilities 1,710.46
Total of other current liabilities 1,710.46
Provisions, current 1,326.73
Current tax liabilities (Net) 4,060.74
Deferred government grants, Current
Total current liabilities 26,541.42
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 48,137.49
Total equity and liabilites 1,87,048.02
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block

Textual Information(1) Refer the financial results pdf uploaded on stock exchange for the full notes



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss (44.06) 17.53
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income 44.06 (17.53)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 21,124.26
Adjustments for reconcile profit (loss)
Adjustments for finance costs (180.96)
Adjustments for decrease (increase) in inventories (65.56)
Adjustments for decrease (increase) in trade receivables, current (2,715.10)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (1,279.59)
Adjustments for decrease (increase) in other non-current assets 1,912.26
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 401.45
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 820.32
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 795.67
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 38.29
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss (14.59)
Adjustments for provisions, current 353.05
Adjustments for provisions, non-current (46.58)
Adjustments for other financial liabilities, current 428.38
Adjustments for other financial liabilities, non-current 758.63
Adjustments for unrealised foreign exchange losses gains (89.64)
Adjustments for dividend income 0.00
Adjustments for interest income (254.16)
Adjustments for share-based payments 733.43
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 6.43
Other adjustments to reconcile profit (loss) 9,099.78
Other adjustments for non-cash items 2,243.53
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 13,453.36
Net cash flows from (used in) operations 34,577.62
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 3,187.11
Other inflows (outflows) of cash 398.03
Net cash flows from (used in) operating activities 31,788.54
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 10,794.10
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 3.02
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 448.61
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 695.20
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 0.00
Proceeds from sales of investment property 41,246.22
Purchase of investment property 2,484.76
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 729.27
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 47,855.92
Cash advances and loans made to other parties 73.60
Cash receipts from repayment of advances and loans made to other parties 5.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 30.61
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (20,905.43)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.64
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 7,133.75
Dividends paid 2,072.88
Interest paid 1,912.26
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (11,118.25)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (235.14)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents (26.89)
Net increase (decrease) in cash and cash equivalents (262.03)
Cash and cash equivalents cash flow statement at beginning of period 2,268.38
Cash and cash equivalents cash flow statement at end of period 2,006.35





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 B S R & Co. LLP Yes 31-07-2028


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Metropolis Healthcare Limited Amin's Pathology Laboratory Private Limited Subsidary Purchase of goods or services 3,000.00 NA 484.39 (140.17) (142.83)
2 Metropolis Healthcare Limited Amin's Pathology Laboratory Private Limited Subsidary Sale of goods or services 100.00 NA 0.64 19.78 52.35
3 Metropolis Healthcare Limited Dapic Metropolis Healthcare Private Limited Subsidary Sale of goods or services 180.00 NA 0.00 35.00 35.00
4 Metropolis Healthcare Limited Ekopath Metropolis Lab Services Private Limited Subsidary Sale of goods or services 450.00 NA 10.37 68.48 35.26
5 Metropolis Healthcare Limited Metropolis Healthcare (Zambia) Limited Subsidary Sale of goods or services 1,100.00 NA 425.59 486.84 178.24
6 Metropolis Healthcare Limited Metropolis Healthcare (Tanzania) Limited Subsidary Sale of goods or services 450.00 NA 172.14 78.04 32.19
7 Metropolis Healthcare Limited Metropolis Star Lab Kenya Limited Subsidary Sale of goods or services 2,000.00 NA 608.49 520.71 334.26
8 Metropolis Healthcare Limited Metropolis Healthcare Lanka (Pvt.) Limited Subsidary Sale of goods or services 300.00 NA 108.60 109.03 230.46
9 Metropolis Healthcare Limited Metropolis Healthcare Ghana Limited Subsidary Sale of goods or services 1,200.00 NA 561.39 248.95 78.94
10 Metropolis Healthcare Limited Metropolis Bramser Lab Services (Mtius) Limited Subsidary Sale of goods or services 360.00 NA 0.00 19.96 21.23
11 Metropolis Healthcare Limited Metropolis Healthcare Uganda Ltd Subsidary Sale of goods or services 370.00 NA 138.00 260.55 221.14
12 Metropolis Healthcare Limited Dr. Duru Shah Relative of Director Sale of goods or services 50.00 NA 6.28 2.82 3.43
13 Metropolis Healthcare Limited Centre for Digestive and Kidney Diseases (India) Pvt Ltd Entity with common directorship Sale of goods or services 1,000.00 NA 396.02 253.30 138.81
14 Metropolis Healthcare Limited Dr. Sushil Shah Director Any other transaction Rent 150.00 NA 69.82 19.90 0.00
15 Metropolis Healthcare Limited Centralab Healthcare Services Private Limited Subsidary Sale of goods or services 450.00 NA 100.93 (809.74) 995.25
16 Metropolis Healthcare Limited Metropolis Star Lab Kenya Limited Subsidary Any other transaction Royalty 550.00 NA 188.60 0.00 0.00
17 Metropolis Healthcare Limited Ekopath Metropolis Lab Services Private Limited Subsidary Interest received 6.08 NA 3.00 2.70 0.45
18 Metropolis Healthcare Limited Metropolis Healthcare Lanka (Pvt) Limited Subsidary Interest received 1.12 NA 0.55 0.00 11.92
19 Metropolis Healthcare Limited DAPIC Metropolis Healthcare Private Limited Subsidary Interest received 408.00 NA 2.58 0.00 1.17
20 Metropolis Healthcare Limited Ameera Shah Key Managerial Personnel Remuneration 1,337.17 NA 217.55 0.00 0.00
21 Metropolis Healthcare Limited Surendran Chemmenkotil Key Managerial Personnel Remuneration 1,191.40 NA 220.38 0.00 0.00 Textual Information(1)
22 Metropolis Healthcare Limited Kamlesh C Kulkarni Key Managerial Personnel Remuneration 1,000.00 NA 30.11 0.00 0.00 Textual Information(2)
23 Metropolis Healthcare Limited Vivek Gambhir Independent Director Remuneration 30.00 NA 2.25 0.00 0.00
24 Metropolis Healthcare Limited Sanjay Bhatnagar Independent Director Remuneration 30.00 NA 5.75 0.00 0.00
25 Metropolis Healthcare Limited Anita Ramachandran Independent Director Remuneration 30.00 NA 0.00 0.00 0.00
26 Metropolis Healthcare Limited Subramanian Ranganathan Independent Director Remuneration 30.00 NA 4.00 0.00 0.00
27 Metropolis Healthcare Limited DAPIC Metropolis Healthcare Private Limited Subsidary Any other transaction Investment in OCD 4,000.00 NA 0.00 0.00 3,361.00
28 Metropolis Healthcare Limited Scientific Metropolis Pathology Private limited Subsidary Any other transaction Investment in OCD 9,000.00 NA 0.00 0.00 5,903.10
29 Metropolis Healthcare Limited DAPIC Metropolis Healthcare Private Limited Subsidary Loan 4,000.00 NA 10.00 0.00 60.00 Loan 8.2500 1 Year Unsecured Loan to be utiilized for working capital requirements of the borrower
30 Ekopath Metropolis Lab Services Private Limited Dr Ronika Baruha Director Purchase of goods or services 50.00 NA 22.80 0.00 0.00
31 Ekopath Metropolis Lab Services Private Limited Dr Shyam Baruha Relative of Director Purchase of goods or services 4.00 NA 1.55 0.00 0.00
32 Ekopath Metropolis Lab Services Private Limited Dr Ronika Baruha Director Any other transaction Rent 12.00 NA 4.61 0.00 2.71
33 Ekopath Metropolis Lab Services Private Limited Dr Shyam Baruha Relative of Director Any other transaction Rent 12.00 NA 4.61 0.00 0.17
34 Scientific Metropolis Pathology Private limited Dr Ashok Sharma Director Any other transaction Investment in Equity Shares 0.12 NA 0.00 0.11 0.11
35 Scientific Metropolis Pathology Private limited Dr Ashok Sharma Director Any other transaction Investment in OCD 900.00 NA 0.00 0.00 655.90
36 Metropolis Healthcare Limited Core Diagnostics Private Limited Subsidary Sale of goods or services 1,800.00 NA 54.71 0.00 258.22
37 Metropolis Healthcare Limited Core Diagnostics Private Limited Subsidary Purchase of goods or services 1,800.00 NA 448.61 0.00 (277.92)
38 Metropolis Healthcare Limited Scientific Metropolis Pathology Private limited Subsidary Sale of goods or services 450.00 NA 22.12 0.00 10.03
39 Metropolis Healthcare Limited Sushil Shah Director Purchase of goods or services 330.00 NA 57.47 0.00 0.00
40 Metropolis Healthcare Limited Sameer Patel Key Managerial Personnel Remuneration 1,000.00 NA 87.25 0.00 0.00 Textual Information(3)
41 Metropolis Healthcare Limited Aditya Shinde Director Remuneration 150.00 NA 47.36 0.00 0.00 Textual Information(4)
42 Metropolis Healthcare Limited Avadhut Joshi Director Remuneration 150.00 NA 63.97 0.00 0.00 Textual Information(5)
43 Metropolis Healthcare Limited Alangadan Kannan Director Remuneration 150.00 NA 56.14 0.00 0.00 Textual Information(6)
44 Metropolis Healthcare Limited Dinesh Chauhan Director Remuneration 160.00 NA 122.97 0.00 0.00 Textual Information(7)
45 Metropolis Healthcare Limited Ms. Purvi Sheth Independent Director Remuneration 15.00 NA 3.25 0.00 0.00
46 Metropolis Healthcare Limited Mr. Rehan Khan Independent Director Remuneration 15.00 NA 3.75 0.00 0.00
47 Metropolis Healthcare Limited Metropolis Foundation Subsidary Investment 100.00 NA 0.00 0.00 2.00
48 Metropolis Healthcare Limited Dr.Aparna Rajadhyaksha Non-Executive Non-Independent Director Purchase of goods or services 45.00 NA 36.00 0.00 43.01
49 Metropolis Healthcare Limited Metropolis Quality Solutions Private Limited Subsidary Any other transaction Investment in Equity Shares 1.00 NA 1.00 0.00 1.00
Total value of transaction during the reporting period 4,805.60



Text Block

Textual Information(1) The approved transaction limits include engagements in the capacity of Chief Executive Officer as well as Managing Director.
Textual Information(2) The Audit Committee approval of 10 crore collectively covers the remuneration of Key Managerial Personnel, including the Chief Financial Officer and Company Secretary.
Textual Information(3) The Audit Committee approval of 10 crore collectively covers the remuneration of Key Managerial Personnel, including the Chief Financial Officer and Company Secretary.
Textual Information(4) Aditya Shinde is a director of subsidiary
Textual Information(5) Avadhut Joshi is a director of subsidiary
Textual Information(6) Alangadan Kannan is a director of subsidiary
Textual Information(7) Dinesh Chauhan is a director of subsidiary